Price T Rowe Associates Inc Blueprint Medicines Corp Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 5,679,089 shares of BPMC stock, worth $504 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
5,679,089
Previous 5,387,267
5.42%
Holding current value
$504 Million
Previous $498 Million
0.6%
% of portfolio
0.06%
Previous 0.06%
Shares
17 transactions
Others Institutions Holding BPMC
# of Institutions
379Shares Held
61.5MCall Options Held
1.6MPut Options Held
1.41M-
Vanguard Group Inc Valley Forge, PA6.77MShares$601 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$590 Million0.02% of portfolio
-
State Street Corp Boston, MA2.5MShares$222 Million0.01% of portfolio
-
William Blair Investment Management, LLC Chicago, IL1.94MShares$173 Million0.44% of portfolio
-
Geode Capital Management, LLC Boston, MA1.49MShares$132 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.3B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...